
A peek inside some leading research labs shows how scientists-turned-detectives are painstakingly decoding what causes autoimmune diseases and how to stop the immune system from attacking you instead of protecting you.
It’s a huge challenge. By the National Institutes of Health’s newest count there are about 140 autoimmune diseases affecting tens of millions of people.
Unraveling them requires patience, persistence — and sophisticated technology to even see the suspects. Researchers use laser-powered machinery and brightly colored fluorescent dyes to tell rogue cells from normal ones.
Take Type 1 diabetes, caused when cells in the pancreas that produce insulin are gradually killed off by rogue T cells. In a biomedical engineering lab at Johns Hopkins University, researchers examine mouse pancreas cells on a computer screen. Red marks the killer cells. In yellow are “peacemaker” cells that are supposed to tamp down autoimmune reactions – but they’re outnumbered.
Another type of immune cell, B cells, drive autoimmune diseases by producing antibodies that mistake healthy tissue for foreign invaders. At NIH, Dr. Iago Pinal-Fernandez studies myositis, a poorly understood group of muscle-weakening diseases. His research shows rogue antibodies don’t just damage muscles by latching onto their surface. They can sneak inside muscle cells and disrupt their normal functions in ways that help explain varying symptoms.
“When I started, nothing was known about the type of autoimmune disease we study. Now finally we’re able to tell patients, ’You have this disease and this is the mechanism of disease,” he said.
In another NIH lab, Dr. Mariana Kaplan’s team is hunting the root causes of lupus and other autoimmune diseases — what makes the immune system run amok in the first place — and why they so often strike women.
Today's drugs tamp down symptoms but don't correct the problem. Now in early-phase clinical trials are treatments that instead aim to fix dysfunctional immune pathways.
At Hopkins, scientists are working on next-generation versions, not yet ready to try in people. In one lab, they're developing nanoparticle-based treatment to dial down pancreas-killing cells in Type 1 diabetes and ramp up “peacemaker” cells.
And in another Hopkins lab, researchers are developing what they hope will become more precise treatments for rheumatoid arthritis, lupus and other antibody-driven illnesses – drugs that search out and destroy “bad” B cells.
—-
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
This is a documentary photo story curated by AP photo editors.
NEUESTE BEITRÄGE
- 1
The most effective method to Guarantee Simple Availability in Seniors' SUVs19.10.2023 - 2
Instructions to Keep up with Your Traded Teeth for Life span16.10.2023 - 3
Experience Sports in Dubai: A Daredevil's Aide06.06.2024 - 4
Misinterpretations and Mistakes Portrayed by Hollywood in the General set of laws30.06.2023 - 5
Novo Nordisk gears up for December Ozempic launch in India, sources say03.12.2025
Ähnliche Artikel
Why are NASA's Artemis astronauts wearing orange? What are they bringing to space? What to know about the preparation for their moon mission.30.03.2026
Don't miss these five impressive spots in Bangkok03.04.2026
5 Arising Professions in Environmentally friendly power01.01.1
Make your choice for the bird that catches your heart!07.06.2024
Little Italy Mercato brings fresh food and community to downtown San Diego04.04.2026
In the background: Visiting Notable Film Areas All over the Planet05.06.2024
From record warming to rusting rivers, 2025 Arctic Report Card shows a region transforming faster than expected16.12.2025
Artemis 2 moon rocket gets 'America 250' paint job | Space photo of the day for Dec. 23, 202523.12.2025
How a niche Catholic approach to infertility treatment became a new talking point for MAHA conservatives12.12.2025
Tesla Stock Hasn’t Looked This Cheap in a While02.04.2026














